58,898 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Acquired by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 58,898 shares of the biotechnology company’s stock, valued at approximately $448,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Counterweight Ventures LLC increased its position in shares of BioCryst Pharmaceuticals by 591.7% in the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock valued at $710,000 after buying an additional 79,884 shares in the last quarter. ProShare Advisors LLC grew its stake in BioCryst Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock valued at $246,000 after acquiring an additional 4,041 shares during the last quarter. XTX Topco Ltd increased its holdings in BioCryst Pharmaceuticals by 299.0% during the 2nd quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock valued at $970,000 after acquiring an additional 117,607 shares in the last quarter. Seven Eight Capital LP raised its position in BioCryst Pharmaceuticals by 1,407.1% during the second quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock worth $1,048,000 after acquiring an additional 158,358 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BCRX has been the subject of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. JMP Securities raised their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. Barclays upped their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Stock Up 1.5 %

BCRX opened at $7.60 on Monday. The company’s 50-day moving average price is $7.66 and its 200 day moving average price is $7.25. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -12.46 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same quarter in the previous year, the company posted ($0.19) earnings per share. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.